NCT02518555View on ClinicalTrials.gov

Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

January 12, 2016

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2025

Conditions
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Interventions
BIOLOGICAL

Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed

Given IM

DRUG

Ibrutinib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

BIOLOGICAL

Pneumococcal 13-valent Conjugate Vaccine

Given IM

OTHER

Quality-of-Life Assessment

Ancillary studies

BIOLOGICAL

Trivalent Influenza Vaccine

Given IM

Trial Locations (1)

43210

Ohio State University Comprehensive Cancer Center, Columbus

Sponsors

Collaborators (1)

Pharmacyclics LLC.
All Listed Sponsors
collaborator

Pharmacyclics LLC.

INDUSTRY

lead

Jennifer Woyach

OTHER

NCT02518555 - Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Biotech Hunter | Biotech Hunter